Serotonin (5-hydroxytryptamine; 5-HT) produces a wide variety of biological activities on many organ systems including the central nervous, gastrointestinal, and cardiovascular systems. These responses to 5-HT are mediated by its receptors on the cell membranes. To date, there are at least 16 identified subtypes of 5-HT receptors, which are now categorized into five main classes (5-HT 1 , 5-HT 2 , 5-HT 3 , 5-HT 4 , and 5-HT 7 ).
Ketanserin, a 5-HT 2 receptor antagonist, shows high affinity for 5-HT 2 receptors on platelets and inhibits 5-HT-induced platelet aggregation and vasoconstriction. 12) However, this compound shows relatively high affinity for adrenergic (a 1 ) receptors, in addition to 5-HT 2 receptors. 13, 14) Sarpogrelate, a more selective 5-HT 2 antagonist, has been developed, and is now clinically available for the treatment of peripheral arterial occlusive diseases. 15, 16) We previously reported that [2-(4-phenylbutyl)phenoxy]-alkylamine derivatives have high affinity for both 5-HT 2 and dopamine-2 (D 2 ) receptors. 17) In the course of a study of [2-(w-phenylalkyl)phenoxy]alkylamine derivatives, [2-(2-phenyllethyl)phenoxy]alkylamine derivatives with a pyrrolidine or piperidine moiety in the structure showed relatively potent and selective affinity for 5-HT 2 receptors. Thus, we have attempted to synthesize highly potent and selective antagonists for peripheral 5-HT 2 receptors on blood vessels and platelets. In this paper, we describe the synthesis and structure-activity relationships (SAR) of these compounds. We also report biological activities of (S)-27, the most active compound as a peripheral 5-HT 2 antagonist, in comparison with ketanserin and sarpogrelate.
Chemistry The phenol derivatives 4-8 were synthesized as shown in Chart 1. Aldehydes 1 and phosphonium chloride 2 were subjected to the Wittig reaction to give the corresponding olefins 3, which were then converted to the phenol derivatives 4-8 by catalytic hydrogenation.
The syntheses of the racemic cyclic amino derivatives having an w-phenyl ring 11-43 are outlined in Chart 2. Piperidine (XϭCH 2 ) and morpholine (XϭO) derivatives (11-17, 20-26, 29, 30) were synthesized as described below. Compounds 10 were prepared by the alkylation of 4-8 with tosylates (9: R 2 ϭOTs) (method A), or by means of the Mitsunobu reaction 18) between 4-8 and a hydroxy derivative (9: R 2 ϭOH) (method B). The resulting compounds 10 were reduced with lithium aluminum hydride to give N-methylated (N-Me) compounds (11) (12) (13) (14) (15) (16) (17) The synthesis of the N-methylpyrrolidine derivative having an w-cyclohexane, 48, is shown in Chart 3. 2-Benzyloxybenzylchloride 44 was converted to the corresponding Grignard reagent and the Grignard reagent was treated with cyclohexanecarboxaldehyde to afford 45. The hydroxy group of 45 was replaced with a chlorine atom by thionyl chloride, and the chlorine atom was replaced with a hydrogen atom by tributyltin hydride to provide 46. Removal of the benzyl group by catalytic hydrogenation afforded phenol 47, which was then treated with 2-(2-chloroethyl)-1-methylpyrrolidine hydrochloride in the presence of tert-BuOK to give 48.
The syntheses of the optically active pyrrolidine intermediates ((S)-51, (R)-55, (S)-55, and (S)-60) are outlined in Charts 4-6. They were performed as follows: The tosylate (S)-51 was synthesized from the commercially available 2-pyrrolidinemethanol (S)-49 through protection by ethyl chloroformate to give carbamate (S)-50, and tosylation (Chart 4).
The tosylate (R)-55 was prepared in four steps starting from the tosylate (R)-51 (Chart 5). The one carbon elongation of (R)-51 with sodium cyanide provided (R)-52, and the resulting nitrile group was hydrolyzed in an acidic condition to give an ester (R)-53. The ester (R)-53 was reduced with lithium aluminum hydride to give an alcohol (R)-54, which was then converted to the tosylate (R)-55. The enantiomer of (R)-55, (S)-55 was prepared in the same manner. The tosylate (S)-60 was prepared in five steps starting from the alcohol (S)-50 (Chart 6). The Swern oxidation 19) of the alcohol (S)-50 provided an aldehyde (S)-56, which was then subjected to the Wittig reaction to give an a,b-unsaturated ester (S)-57. The ester (S)-57 was hydrogenated, and the following reduction of the saturated ester (S)-58 with lithium aluminum hydride gave an alcohol (S)-59, which was then converted to the tosylate (S)-60.
The syntheses of the target compounds ((R)-27, (S)-27, (S)-62, and (S)-63) are shown in Chart 7. The phenol 4a (R 1 ϭ3-OMe) was alkylated with the tosylates ((S)-51, (R)-55, (S)-55, and (S)-60) to give carbamates, which were then reduced with lithium aluminum hydride to give the desired products. This was followed by their corresponding salt formation.
Results and Discussion
All compounds have diphenylalkylene structures connecting two phenyl parts in this series. In the previous paper, we reported the relationship between the alkylene chain length and D 2 receptor binding of 3-dimethylamino-1-(w-phenylalkylphenoxy)-2-propanol derivatives. 17) Only the tetramethylene derivative showed D 2 receptor affinity, and the tetramethylene derivatives with a piperidine moiety, including compound 13, exhibited high affinity for 5-HT 2 and D 2 receptors. Thus, we examined the influence of the alkylene chain length in the diphenylalkylene moiety of compound 13 ( Table 1 ). The compounds in Table 1 exhibited high affinity for 5-HT 2 receptors with their IC 50 values between 1.9 and 31 nM. Among them, the dimethylene derivative 11 and the tetramethylene derivative 13 were highly potent; their IC 50 values were smaller than that of M-1, the active metabolite of sarpogrelate. In the D 2 receptor binding studies, the tetramethylene derivative 13 exhibited high affinity with an IC 50 of 9.2 nM, while other compounds had markedly reduced activity (IC 50 s Ͼ150 nM). This is consistent with the results reported for 3-dimethylamino-1-(w-phenylalkylphenoxy)-2-propanol derivatives. 17) Among the [2-(w-phenylalkyl)phenoxy]alkylamine derivatives with a piperidine or pyrrolidine moiety, the dimethylene and tetramethylene derivatives (16) (17) (18) (19) were examined in 5-HT 2 and D 2 receptor binding assays ( Table 2 ). The dimethylene derivatives 16 and 18 showed higher 5-HT 2 and lower D 2 receptor affinity compared with the corresponding tetramethylene derivatives, 17 and 19, respectively. Thus, the dimethylene chain was suitable for selectivity of the 5-HT 2 receptor.
The dimethylene derivatives with a cyclic amino group were examined in 5-HT 2 and D 2 receptor binding assays (Table 3) . The introduction of a 3-methoxy group on the wphenyl ring increased the affinity for the 5-HT 2 receptor (16 vs. 21, 18 vs. 27), which is consistent with our previous re-sults. 17) Among this series of compounds, the 5-HT 2 and D 2 receptor affinity of N-Me compounds (11, 21, 23, 25, 27) were higher than those of the corresponding N-H compounds (20, 22, 24, 26, 28). Compound 21, which has a 2-(2-piperidinylethyl) structure, showed high affinity for 5-HT 2 receptors. However, 21 also showed high affinity for D 2 receptors, and its D 2 /5-HT 2 ratio was smaller than that of 11. The D 2 receptor affinity of compound 23 was six-fold lower than that of 11, and its 5-HT 2 receptor affinity was also slightly lower than 11. It is interesting to note that these three compounds (11, 21, 23) with potent affinity (IC 50 Ͻ10 nM) for 5-HT 2 receptors, have three carbon atoms between the piperidine nitrogen and the etheral oxygen. In contrast, the other piperidine derivatives such as 29 with five carbon atoms and 30 with two carbon atoms between the piperidine nitrogen and etheral oxygen, respectively, were less active. In the previous paper, we reported that the D 2 receptor affinity depends on the lipophilicity around the amino moiety in a series of compounds. 17) Morpholine derivative 25, which has an oxygen instead of a methylene group at the 4-position of piperidine, was prepared in an attempt to reduce the D 2 receptor affinity by decreasing the lipophilicity around the amino moiety. As expected, the D 2 receptor affinity of 25 was lower than that of the piperidine derivative, 11. However, the 5-HT 2 receptor affinity of 25 also decreased in parallel. Compound 27, which has a pyrrolidine ring instead of a piperidine ring, was as potent as 11 and 21 for its 5-HT 2 receptor affinity, but less potent for its D 2 receptor affinity compared to 11 and 21. Among these three compounds, 27 exhibited the highest D 2 /5-HT 2 ratio (340), suggesting a high selectivity. The pyrrolidine derivatives, therefore, seemed superior to the piperidine derivatives as selective 5-HT 2 antagonists.
The effect of the substituent on the w-phenyl group was examined (Table 4) . Most compounds show high affinity for 5-HT 2 receptors, regardless of the type of the substituent. Compounds substituted at the 3-position (27, 34, 37) of the w-phenyl ring showed higher affinity than those substituted at the 2-or 4-position (31, 33, 36 or 32, 35, 38). The methoxy-substituted compounds showed slightly more potent activity than their corresponding ethoxy compounds. Compounds 37 and 39, having a chlorine and a fluorine atom, respectively, on the w-phenyl ring also showed more potent activity than the bromo analog 40. These results show that the introduction of a bulky substituent decreases the affinity for 5-HT 2 receptors. The introduction of a hydrophilic hydroxy group (43) instead of the etheral O-methyl group of 27 also decreased the 5-HT 2 receptor affinity. The reduction of the w-phenyl ring, which leads to an w-cyclohexane in compound 48, maintained the 5-HT 2 receptor affinity. In the case of 2-(1-methyl-2-pyrrolidinylethyl) derivatives, as indicated in changed substituent on the w-phenyl ring were not as potent and selective for 5-HT 2 receptors as 27.
Although 27 had potent and selective affinity for 5-HT 2 receptors, this compound has the asymmetric carbon atom at the 2-position of the pyrrolidine ring. Therefore, each of the enantiomers was prepared to examine its binding affinity for 5-HT 2 and D 2 receptors ( Table 5 ). The compound with (S ) configuration, (S)-27, exhibited higher 5-HT 2 receptor affinity and lower D 2 receptor affinity than racemic 27. These results indicate that (S)-27 is the active enantiomer in 5-HT 2 receptor affinity. Table 6 shows the effect of the alkylene chain attached to the 2-position of pyrrolidine. Among these compounds, (S)-27 (nϭ2) showed the highest affinity for 5-HT 2 receptors. Compared with (S)-27, (S)-62 (nϭ1) and (S)-63 (nϭ3) showed lower affinity. These results show that the 5-HT 2 receptor affinity was the highest for pyrrolidine derivatives with three carbon atoms between the pyrrolidine nitrogen and etheral oxygen. This is consistent with results in the study of the piperidine derivatives. Table 7 shows the IC 50 values (mM) for the test compounds ((S)-27, ketanserin, sarpogrelate, and M-1, the active metabolite of sarpogrelate) against in vitro human platelet aggregation. (S)-27 inhibited platelet aggregation in a concentration-dependent manner with an IC 50 value of 0.057 mM. Ketanserin and M-1 also inhibited platelet aggregation, but these agents were less potent than (S)-27. Sarpogrelate produced the minimum inhibition on platelet aggregation. These results clearly indicate that (S)-27 has more potent in vitro antiaggregatory activity compared to those of sarpogrelate, M-1, and ketanserin.
The ex vivo effects of 5-HT 2 antagonists, (S)-27, ketanserin and sarpogrelate on 5-HT-induced platelet aggregation were examined in cats (Fig. 1) . Single bolus administration of (S)-27 (100 mg/kg, i.v.) resulted in a marked inhibition (90%) of platelet aggregation at 0.5 h postdose. The inhibition disappeared gradually, but was still evident even at 6 h (29% inhibition). Ketanserin (100 mg/kg, i.v.) also showed an inhibition (61%) at 0.5 h postdose, but the extent of the inhibition was smaller than (S)-27. In addition, the effect of ketanserin disappeared at 4 h postdose. Sarpogrelate even at the highest dose (1000 mg/kg, i.v.) failed to inhibit platelet aggregation, indicating weak efficacy of this agent. These results suggest that (S)-27 is a potent antiplatelet agent with long duration of action in vivo.
The addition of (S)-27 alone to platelet-rich plasma (PRP) did not cause any platelet aggregation up to 1 mM. Thus, this compound is unlikely to have any agonistic activity for 5- In conclusion, we found that new [2-(2-phenylethyl)phenoxy]alkylamine derivatives with a pyrrolidine or piperidine moiety in their structure have high affinity for 5-HT 2 receptors but low affinity for D 2 receptors. Among these compounds, (S)-27 exhibited the highest selectivity and potency for 5-HT 2 receptors in the binding assays. This compound was also effective in inhibiting 5-HT-induced vasoconstriction in vitro and platelet aggregation both in vitro and ex vivo.
Experimental
Melting points were determined with a Yanagimoto micro melting point apparatus and were uncorrected.
1 H-NMR spectra were obtained on a JEOL EX270 spectrometer and were reported as d values relative to Me 4 Si as the internal standard. Abbreviations of the 1 H-NMR peak patterns are as follows: brϭbroad, sϭsinglet, dϭdoublet, tϭtriplet, qϭquartet, and mϭmulti-plet. IR spectra were taken on a JASCO FT/IR-8900 spectrometer. Merck Silica gel 60 (230-400 mesh) was used in the column chromatography. Tetrahydrofuran, N,N-dimethylacetamide, and dimethylsulfoxide are abbreviated as THF, DMA, and DMSO, respectively. 16) 4a (R 1 ϭ3-OMe) (790 mg, 3.46 mmol) in DMA (8 ml) was added tert-BuOK (388 mg, 3.46 mmol) and the mixture was stirred at 0°C for 10 min. Then a solution of 1-tert-butoxycarbonyl-3-( p-toluenesulfonyloxymethyl)piperidine 9 (mϭ1, XϭCH 2 ) (1.28 g, 3.46 mmol) in DMA (7 ml) was added and the mixture was stirred overnight at room temperature. The resulting suspension was diluted with EtOAc and washed with H 2 O and brine. The organic layer was dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ5/1-4/1) to give 10 (mϭ1, nϭ2, R 1 ϭ3-OMe, XϭCH 2 ) (1.09 g, 2.56 mmol, 74%) as a colorless oil. 1 ) (850 mg, 2.00 mmol) in THF (6 ml) was added to a suspension of LiAlH 4 (113 mg, 2.98 mmol) in THF (10 ml) at room temperature. The mixture was stirred at room temperature for 2 h and then refluxed for 2.5 h. The mixture was cooled, and to the mixture Na 2 SO 4 decahydrate was added slowly and the slurry was then stirred for 30 min. The insoluble material was filtered away, and the filtrate was concentrated. The resulting residue was chromatographed on a silica gel column (CH 2 Cl 2 /MeOHϭ20/1-10/1) to give 3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl-1-methylpiperidine (520 mg, 1.53 mmol, 77%) as a colorless oil. This oil was dissolved in EtOAc (5 ml) and was treated with 4 N HCl in dioxane (1.15 ml, 4.59 mmol). The mixture was stirred at room temperature for 10 min and concentrated. The oily residue was dissolved in a mixture of EtOAc/CH 2 Cl 2 ϭ9/1, and the solution was allowed to stand at room temperature. The precipitate formed was collected by filtration to give 11 (443 mg, 1.18 mmol, 77%) as colorless crystals.
1-tert-Butoxycarbonyl-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxymethyl]piperidine (10: m‫,1؍‬ n‫,2؍‬
R 1 ‫-3؍‬OMe, X‫؍‬CH 2 ) (Method A) To a solution of 2-[2-(3-methoxyphenyl)ethyl]phenol
3-[2-[2-(3-Methoxyphenyl)ethyl]phenoxy]methylpiperidine Hydrochloride (20)
2 ) (240 mg, 0.564 mmol) in EtOAc (4 ml) was treated with 4 N HCl in dioxane (4 ml) and the mixture was stirred at room temperature for 3 h and then concentrated. The oily residue was dissolved in EtOAc, and the solution was allowed to stand at room temperature. The precipitate formed was collected by filtration to give 20 (183 mg, 0.506 mmol, 90%) as colorless crystals.
Similarly, the morpholine derivatives 25 and 26 and other piperidine derivatives 11-16, 20-22, and 29 were prepared by alkylation of phenol derivatives 4-8 20) with tosylates, followed by a treatment with lithium aluminum hydride or HCl as described in method A. 1 ϭ3-OMe, Xϭ CH 2 ) (482 mg, 1.17 mmol) in THF (5 ml) was treated with a suspension of LiAlH 4 (44.5 mg, 1.17 mmol) in THF (5 ml) under cooling. The resulting mixture was refluxed for 1 h and then cooled. To the resulting suspension was slowly added Na 2 SO 4 decahydrate and the mixture was stirred for 30 min. The insoluble material was filtered away and the filtrate was concentrated. The resulting residue was chromatographed on a silica gel column (CH 2 Cl 2 /MeOHϭ20/1-10/1) to give 4-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]-1-methylpiperidine (220 mg, 0.68 mmol, 58%) as a light yellow oil. This oil was dissolved in EtOAc (5 ml) and was treated with 4 N HCl in dioxane (0.25 ml, 1.00 mmol). The resulting solution was concentrated. The oily residue was dissolved in EtOAc (20 ml), and the solution was allowed to stand at room temperature. The precipitate formed was collected by filtration to give 23 (170 mg, 0.47 mmol, 69%) as colorless crystals.
1-tert-Butoxycarbonyl-4-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]-
Similarly, other piperidine derivatives 17, 24, and 30 were prepared by means of the Mitsunobu reaction 18) between the phenol derivatives 4-8 20) and a hydroxy derivative (9), followed by a treatment with lithium aluminum hydride or HCl as described in method B. orless oil. This oil was dissolved in EtOAc (5 ml) and was treated with 4 N HCl in dioxane (0.63 ml, 2.52 mmol). The resulting solution was concentrated. The oily residue was dissolved in EtOAc (10 ml), and the solution was allowed to stand at room temperature. The precipitate formed was collected by filtration to give 18 (130 mg, 0.38 mmol, 24%) as colorless crystals.
Other pyrrolidine derivatives (19, 31-43) were similarly prepared with the exceptions of 27 which was prepared by method D, and 28 which was prepared by method A. This oil was dissolved in EtOAc (100 ml) and was treated with 4 N HCl in dioxane (5.0 ml, 20 mmol). The resulting solution was concentrated. The oily residue was dissolved in EtOAc (150 ml), and the solution was allowed to stand at room temperature. The precipitate formed was collected by filtration to give 27 (4.88 g, 13.0 mmol, 77%) as colorless crystals. ) as a colorless oil. This oil was dissolved in dioxane (5 ml) and treated with 4 N HCl in dioxane (0.50 ml, 2.0 mmol). The resulting solution was concentrated. The oily residue was dissolved in EtOAc (10 ml), and the solution was allowed to stand at room temperature. The precipitate formed was collected by filtration to give 28 (344 mg, 0.95 mmol, 61%) as colorless crystals.
2-[2-[2-[2-(3-Methoxyphenyl

2-[2-[2-[2-(3-Methoxyphenyl)ethyl]phenoxyl]ethyl]pyrrolidine Hydrochloride (28) (Method
2-(2-Benzyloxybenzyl)-1-cyclohexylethane-1-ol (45)
A solution of 2-benzyloxybenzylchloride 44 (41.5 g, 178 mmol) in THF (50 ml) was added to a suspension of Mg (4.33 g, 178 mmol) and I 2 (trace) in THF (300 ml). The mixture was stirred under reflux for 2 h, and cooled to room temperature. Then cyclohexanecarboxaldehyde (10 g, 89 mmol) was added, and the mixture was stirred overnight at room temperature. The reaction mixture was poured into water and extracted with EtOAc. The organic layer was washed with brine, dried and evaporated. The resulting residue was chromatographed on a silica gel column (EtOAc/hexaneϭ1/19-3/17) to give 45 (17.9 g, 57.7 mmol, 65%) as a colorless oil. 1-Benzyloxy-2-(2-cyclohexylethyl)benzene (46) Triethylamine (4.36 ml, 31.3 mmol) was added to a solution of 2-(2-benzyloxybenzyl)-1-cyclohexylethane-1-ol 45 (8.10 g, 26.1 mmol) in THF (200 ml) and the mixture was stirred at room temperature for 15 min. Then thionyl chloride (2.23 ml, 31.3 mmol) was added, the reaction mixture was stirred overnight at room temperature, and was poured in water and extracted with EtOAc. The organic layer was washed with brine, dried and evaporated. The resulting residue was chromatographed on a silica gel column (EtOAc/hexaneϭ3/97) to give 2- 36 (4H, m), 1.40-1.82 (7H, m) , 2.61-2.74 (2H, m), 5.08 (2H, s), 6.85-6.95 (2H, m), 7.14 (2H, t, Jϭ7.6 Hz), 7.26-7.49 (5H, m).
2-(2-Cyclohexylethyl)phenol (47)
A solution of 1-benzyloxy-2-(2-cyclohexylethyl)benzene 46 (4.51 g, 15.3 mmol) in EtOH (50 ml) was hydrogenated over 5% Pd-C (450 mg) at 60°C for 4 h with stirring. The catalyst was filtered away, and the filtrate was concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ19/1-9/1) to give 47 (2.92 g, 14.3 mmol, 93%) as a colorless solid.
1 H-NMR (CDCl 3 ) d: 0.83- 1.05 (2H, m), 1.09-1.39 (4H, m), 1.43-1.56 (2H, m), 1.60-1.87  (5H, m), 2.54-2.66 (2H, m), 4.69 (1H, s), 6.75 (1H, d, Jϭ7.9 Hz), 6.86 (1H, t, Jϭ7.9 Hz), 7.01-7.14 (2H, m).
2-[2-[2-(2-Cyclohexylethyl)phenoxy]ethyl]-1-methylpyrrolidine Hydrochloride (48) To a solution of 2-(2-cyclohexylethyl)phenol 47 (500 mg, 2.45 mmol) in DMA (10 ml) was added tert-BuOK (549 mg, 4.89 mmol) and the mixture was stirred at room temperature for 30 min. 2-(2-Chloroethyl)-1-methylpyrrolidine hydrochloride (450 mg, 2.44 mmol) was added, and the mixture was stirred at 60°C for 5 h. 2-(2-Chloroethyl)-1-methylpyrrolidine hydrochloride (80 mg, 0.43 mmol) was then added, and the mixture was stirred overnight at room temperature. The resulting solution was diluted with EtOAc and washed with H 2 O and brine. The organic layer was dried and concentrated. The resulting residue was chromatographed on a silica gel column (CH 2 Cl 2 /MeOHϭ97/3) to give 2-[2-[2-(2-cyclohexylethyl)phenoxy]ethyl]-1-methylpyrrolidine (350 mg, 1.11 mmol, 45%) as a colorless oil. This oil was dissolved in dioxane (4 ml) and was treated with 4 N HCl in dioxane (0.83 ml, 3.32 mmol). The resulting solution was concentrated. The oily residue was dissolved in EtOAc (10 ml), and the solution was allowed to stand at room temperature. The precipitate formed was collected by filtration to give 48 (243 mg, 0.69 mmol, 62%) as colorless crystals.
(S)-1-Ethoxycarbonyl-2-hydroxymethylpyrrolidine ((S)-50) To a solution of (S )-2-pyrrolidinemethanol (S )-49 (13.86 g, 137 mmol) in acetone (80 ml) and H 2 O (80 ml) was added triethylamine (19.10 ml, 137 mmol) and the mixture was stirred at 0°C for 15 min. Then ethyl chloroformate (14.35 ml, 151 mmol) was added and the whole was stirred at room temperature for 6 h. The resulting mixture was concentrated and extracted with EtOAc and washed with brine. The organic layer was dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/ EtOAcϭ3/7) to give (S )-50 (20.31 g, 117 mmol, 86%) as a colorless oil. 1-Ethoxycarbonyl-2-(2-hydroxyethyl)pyrrolidine ((S)-54) A solution of (S )-1-ethoxycarbonyl-2-(ethoxycarbonylmethyl)pyrrolidine (S )-53 (11.15 g, 48.6 mmol) in THF (20 ml) was added dropwise to a suspension of LiAlH 4 (1.85 g, 48.7 mmol) in THF (30 ml) at Ϫ10°C. The mixture was stirred at Ϫ10°C for 1 h. To the resulting suspension was slowly added Na 2 SO 4 decahydrate and the slurry was then stirred for 30 min. The insoluble material was filtered away and the filtrate was concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ 3/7) to give (S)-54 (7.07 g, 37.8 mmol, 78%) as a colorless oil. 9 mmol) in THF (50 ml) was added dropwise to a suspension of LiAlH 4 (2.61 g, 48.7 mmol) in THF (50 ml). The mixture was refluxed for 1 h and then cooled. To the resulting suspension was slowly added Na 2 SO 4 decahydrate and the slurry was then stirred for 1 h. The insoluble material was filtered away and the filtrate was concentrated. The resulting residue was chromatographed on a silica gel column (CH 2 Cl 2 /MeOHϭ9/1) to give 2-[2-[2-[2-(3-methoxyphenyl)ethyl]phenoxyl]ethyl]-1-methylpyrrolidine (7.35 g, 21.7 mmol, 95%) as a colorless oil. This oil (7.19 g, 21.2 mmol) was dissolved in dioxane (35 ml) and was treated with 4 N HCl in dioxane (15.9 ml, 63.6 mmol). The mixture was stirred at room temperature for 10 min, then concentrated. The oily residue was dissolved in EtOAc, and the solution was allowed to stand at room temperature. The precipitate formed was collected by filtration to give colorless crystals (7.11 g, 18.9 mmol, 89%). [a] D Ϫ41°(cϭ1.64, MeOH).
(S)-1-Ethoxycarbonyl-2-formylpyrrolidine ((S)-56) To a solution of DMSO (6.85 ml, 96.5 mmol) in CH 2 Cl 2 (120 ml) was added oxalyl chloride (8.42 ml, 97 mmol) and the mixture was stirred at Ϫ60°C for 5 min. (S )-1-Ethoxycarbonyl-2-hydroxymethylpyrrolidine (S )-50 (11.14 g, 64.3 mmol) in CH 2 Cl 2 (30 ml) was then added and the mixture was stirred at Ϫ60°C for 1 h. To the resulting solution was added triethylamine (26.89 ml, 193 mmol) and the mixture was stirred at Ϫ60°C for 1 h. The resulting solution was diluted with CH 2 Cl 2 and washed with H 2 O and brine. The organic layer was dried and concentrated, and the resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ13/7) to give (S)-56 (8.67 g, 50.6 mmol, 79%) as a colorless oil. ϭ3-OMe) (800 mg, 3.50 mmol) in DMA (15 ml) was added tert-BuOK (433 mg, 3.86 mmol) and the mixture was stirred at 0°C for 15 min. A solution of (S )-1-ethoxycarbonyl-2-[3-( p-toluenesulfonyloxy)propyl)pyrrolidine (S )-60 (1.37 g, 3.85 mmol) in DMA (7 ml) was then added and the whole was stirred at room temperature for 3.5 h. The resulting suspension was diluted with EtOAc and washed with H 2 O and brine. The organic layer was dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ4/1) to give (S)-61 (nϭ3) (1.30 g, 3.16 mmol, 90%) as a colorless oil. 09 mmol) in THF (20 ml) was added dropwise to a suspension of LiAlH 4 (350 mg, 9.22 mmol) in THF (15 ml). The mixture was refluxed for 1 h and then cooled. To the resulting suspension was slowly added Na 2 SO 4 decahydrate and the slurry was then stirred for 2 h. The insoluble material was filtered away and the filtrate was concentrated. The resulting residue was chromatographed on a silica gel column (CH 2 Cl 2 /MeOHϭ9/1) to give 2-[3-[2-[2-(3-methoxyphenyl)ethyl]phenoxyl]propyl]-1-methylpyrrolidine (996 mg, 2.82 mmol, 91%) as a colorless oil. To a solution of this oil (880 mg, 2.49 mmol) in EtOH (5 ml) was added citric acid (523 mg, 2.49 mmol) and the mixture was stirred at room temperature for 2 h, then concentrated. The oily residue was dissolved in EtOAc, and the solution was allowed to stand at room temperature. The precipitate formed was collected by filtration to give colorless crystals (1.30 g, 2.38 mmol, 96%). [a] D Ϫ12°(cϭ1.30, MeOH).
5-HT 2 Receptor Binding Assay
The 5-HT 2 receptor binding assay of Leysen et al. 21) was employed with some modifications. It was performed using the 5-HT 2 26) was employed with modifications. It was performed in a similar manner to the 5-HT 2 receptor binding assay, except for the use of the 5-HT 3 antagonist, [ 3 H]GR65630, as the 3 H-ligand.
5-HT-Induced Vasoconstriction Experiment
Contractions of the rat caudal arteries of Van Nueten et al. 27) were employed with some modifications as reported in ref 17 .
5-HT-Induced PRP Aggregation Preparation of Platelets: For in vitro experiments, human blood was withdrawn by venepuncture from normal volunteers, who had not taken any medication for a period of at least 10 d. For ex vivo experiments, blood was withdrawn from the left carotid artery of pentobarbital (40 mg/kg, i.p.)-anesthetized male cats (American Shorthair, Kasho, 2.5-3.6 kg) before and 0.5, 1, 2, 4 and 6 h after intravenous administration of test compounds. Blood samples were collected into plastic syringes containing 3.8% trisodium citrate (1 : 9, v/v). The blood was centrifuged, to obtain PRP, at 150ϫg (human) and 120ϫg (cat) for 15 min at room temperature. Platelet-poor plasma (PPP) was obtained by centrifugation of the remaining blood at 2000ϫg for 10 min. Platelet counts in PRP were adjusted to 3ϫ10 8 /ml (human) and 2.5ϫ10 8 /ml (cat) by adding PPP. Measurements of Platelet Aggregation: All aggregation studies were performed in a 6-channel aggregometer (NKK, Tokyo, Japan). The PRP was incubated at 37°C for 1.5 min in the aggregometer, with stirring (1000 rpm), followed by stimulation with 5-HT (10 mM) combined with collagen (0.125 mg/ml) for human platelets and 5-HT alone (4-8 mM) for cat platelets. Changes in light transmission were recorded for 10 min after the stimulation. The extent of aggregation was estimated by the percent of maximum increase in light transmission, with the PPP representing 100% transmittance. In human platelet studies, test compounds dissolved in saline were added to the PRP before agonist stimulation, and results were expressed as IC 50 values (mM), the concentration produced a 50% inhibition.
